The U.K. regulatory authority approved the Alzheimer’s disease drug, Leqembi, last month. But the U.K. cost-effectiveness watchdog NICE recommends against reimbursement. The U.K. regulatory authority approved the Alzheimer’s disease drug, Leqembi, last month. But the U.K. cost-effectiveness watchdog NICE recommends against reimbursement. Healthcare, /healthcare, Innovation, /innovation, Healthcare, /healthcare, business, pharma & healthcare, standard
